Unfortunately, this thumb’s down vote is not binding. The FDA could still approve aducanumab:
“The nonbinding vote by an advisory panel for the Food and Drug Administration does not mean the agency won’t approve the drug, aducanumab, made by Biogen. But it signals that many experts in the field are not convinced of its effectiveness, another major setback in the long journey to find a treatment for Alzheimer’s that works.”
Market Data 
Markets 
AI
